Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.062 | 0.1904 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0047 | 0.3256 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.002 | 0.062 | 0.5 |
Trypanosoma brucei | unspecified product | 0.002 | 0.062 | 0.1904 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0063 | 0.4781 | 0.4436 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0116 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.062 | 0.1904 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.002 | 0.062 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.002 | 0.062 | 0.1904 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 0.4781 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 0.4781 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0063 | 0.4781 | 0.4436 |
Mycobacterium ulcerans | DNA polymerase IV | 0.002 | 0.062 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0063 | 0.4781 | 0.4436 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.062 | 0.1904 |
Brugia malayi | RNA binding protein | 0.0063 | 0.4781 | 0.4672 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 0.4781 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0063 | 0.4781 | 1 |
Leishmania major | DNA polymerase eta, putative | 0.0033 | 0.1879 | 0.4775 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0047 | 0.3256 | 0.3115 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0025 | 0.1073 | 0.3296 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.062 | 0.1904 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 0.4781 | 1 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.002 | 0.062 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.062 | 0.1904 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.002 | 0.062 | 0.0424 |
Leishmania major | hypothetical protein, conserved | 0.0025 | 0.1073 | 0.1719 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0063 | 0.4781 | 0.4672 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.1073 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0063 | 0.4781 | 0.4672 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.062 | 0.1904 |
Echinococcus granulosus | dna polymerase eta | 0.0047 | 0.3256 | 0.6335 |
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0033 | 0.1879 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.002 | 0.062 | 0.5 |
Brugia malayi | hypothetical protein | 0.0025 | 0.1073 | 0.0887 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.062 | 0.1904 |
Loa Loa (eye worm) | hypothetical protein | 0.0047 | 0.3256 | 0.2811 |
Giardia lamblia | DINP protein human, muc B family | 0.002 | 0.062 | 0.5 |
Schistosoma mansoni | DNA polymerase eta | 0.0047 | 0.3256 | 0.6335 |
Echinococcus multilocularis | dna polymerase eta | 0.0047 | 0.3256 | 0.6335 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.1073 | 0.1719 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.002 | 0.062 | 0.1904 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.002 | 0.062 | 0.1904 |
Leishmania major | DNA polymerase eta, putative | 0.0047 | 0.3256 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.062 | 0.1904 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.1073 | 0.0483 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.002 | 0.062 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0063 | 0.4781 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0116 | 1 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0025 | 0.1073 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.1073 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0063 | 0.4781 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.1073 | 0.1719 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0033 | 0.1879 | 0.4775 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.062 | 0.1904 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.002 | 0.062 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.062 | 0.1904 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0047 | 0.3256 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. | ChEMBL. | 22096101 | |
CC50 (functional) | > 65.91 uM | Huh7 cytotoxicity for Pf inhibitors | Novartis-GNF Malaria Box. | No reference |
CC50 | > 65.91 uM | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | ChEMBL. | 18579783 |
EC50 (functional) | = 0.671 uM | PF proliferation inhibition 3D7 | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 0.671 uM | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
EC50 (functional) | = 0.856 uM | W2 Pf proliferation inhibition | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 0.856 uM | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
IFI promiscuity index | = 0.03774 | IFI promiscuity index | Novartis-GNF Malaria Box. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 18579783 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.